About Hummingbird Bioscience

Hummingbird Bioscience

Hummingbird Bioscience is a clinical-stage biotech company founded in 2015 by a team of interdisciplinary scientists with a shared belief that there is a better way to deliver a new generation of transformative precision medicines.

At Hummingbird, we harness powerful, cutting-edge approaches to systems biology and data science to better understand disease mechanisms and how to treat these, through the development of rationally engineered precision biotherapeutics.

Together we aim to accelerate the journey of new drugs from concept to clinical care.

Industry News

Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy

December 6 2022

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative […]

Clinical Trials

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer

October 25 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets […]

Appointments

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Josh House as Chief Financial Officer

September 1 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, […]

Appointments

Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors

July 26 2021

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, […]

Diseases

Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration to Advance Innovative Immunotherapies

July 12 2021